• Noucor, a leading international B2B pharmaceutical player recently acquired by MCH Private Equity, aims to continue growing through new developments, with both generic products and innovative molecules
  • The new company c\ounts with a proven track-record in the pharmaceutical sector and has a presence in more than 100 markets worldwide, with Asia standing out as main strategic market and one of the main pillars for growth
  • The Noucor brand shows the commitment to innovation and to constant improvement of the new company, offering a top quality service and specific and customised solutions to its clients

Barcelona, December 3rd, 2021 – After an extensive trajectory in the global B2B pharmaceutical sector, Noucor has been created with the support of MCH, one of the most established private equity firms in Spain.

The new company, a result of the spin-off of Uriach’s B2B business, has sales in more than 100 countries and is committed to growing through geographic expansion in markets such as Japan, China and the United States, and new developments in both generic products and innovative molecules.

To this end, Noucor has a fine chemical plant (Urquima), a pharmaceutical plant and a plant for food supplements, enabling it to offer operational excellency, agile execution and cost efficiency.

The value proposition offered by Noucor strengthens its role as a trusted strategic partner in the health ecosystem through a model based on a series of key pillars: to be a trusted and relevant player in the B2B pharmaceutical sector, to constantly commit to research and development and to provide an agile response capacity, pillars that define its strategic model.

Values and Identity of the Noucor Brand

Four brand values identify and reflect the essence of Noucor:

  • Vision: An innovative brand that has a forward-looking perspective, combining the pharmaceutical and chemical industries, through innovative molecules and products capable of improving health.
  • Excellence: A brand that displays its high level of knowledge and experience, transforming all of its talent into reliable and quality responses and solutions.
  • Commitment: A brand committed to always giving its best, through a relationship based on closeness and trust, that always puts its clients first.
  • A brand with the capacity to constantly adapt, that understands the needs of its clients and suppliers and that seeks constant improvement.

The new company places value on innovation and growth, resulting in a modern and strong brand, a very recognisable and distinctive identity in the sector. “Together for health” is the concept that is being presented along with the new brand and that defines and reflects its strategic vision: to promote innovation in the field of health.

“A new stage, a new company, a new brand, that boost our commitment to innovation and turn all our knowledge and experience into quality products and solutions. Noucor has been created to continue growing, to continue improving health” highlighted David Perdigó, CEO of Noucor.

The creation of Noucor enables to strengthen the company´s relationships with its clients through a close and committed collaboration with the aim of promoting the development of products and solutions in the health ecosystem.

About Noucor

Noucor, based in Barcelona, is a Spanish pharmaceutical company whose business is focused on R&D, licensing, manufacturing and supply of pharmaceutical products and which has extensive knowledge and experience offering quality products and solutions in the health ecosystem.

With an international presence in more than 100 countries and three production plants (a fine chemical plant, a pharmaceutical plant and a plant for food supplements), Noucor is a leading partner for the development of value-added pharmaceutical products globally.

Among the most relevant milestones achieved by Noucor, it is worth mentioning the entry of its most successful product, the antihistamine Rupatadine, in key markets such as Japan, South Korea and Canada, and the growth of the generics business in Europe, as well as its expansion in other markets (Canada and Russia mainly).

The company has more than 400 employees and a forecasted turnover of 80M Euros at the end of 2021.